Point Prevalence Survey of Antimicrobial Use in a Malaysian Tertiary Care University Hospital.
antimicrobial
compliance
point prevalence
prescribing
risk
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
04 May 2021
04 May 2021
Historique:
received:
02
04
2021
revised:
29
04
2021
accepted:
02
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Antimicrobial resistance remains a significant public health issue, and to a greater extent, caused by the misuse of antimicrobials. Monitoring and benchmarking antimicrobial use is critical for the antimicrobial stewardship team to enhance prudent use of antimicrobial and curb antimicrobial resistance in healthcare settings. Employing a comprehensive and established tool, this study investigated the trends and compliance of antimicrobial prescribing in a tertiary care teaching hospital in Malaysia to identify potential target areas for quality improvement. A point prevalence survey method following the National Antimicrobial Prescribing Survey (NAPS) was used to collect detailed data on antimicrobial prescribing and assessed a set of quality indicators associated with antimicrobial use. The paper-based survey was conducted across 37 adult wards, which included all adult in-patients on the day of the survey to form the study population. Of 478 patients surveyed, 234 (49%) patients received at least one antimicrobial agent, with 357 antimicrobial prescriptions. The highest prevalence of antimicrobial use was within the ICU (80%). Agents used were mainly amoxicillin/β-lactamase inhibitor (14.8%), piperacillin/β-lactamase inhibitor (10.6%) and third-generation cephalosporin (ceftriaxone, 9.5%). Intravenous administration was ordered in 62.7% of prescriptions. Many antimicrobials were prescribed empirically (65.5%) and commonly prescribed for pneumonia (19.6%). The indications for antimicrobials were documented in the patients' notes for 80% of the prescriptions; however, the rate of review/stop date recorded must be improved (33.3%). One-half of surgical antimicrobial prophylaxis was administered for more than 24 h. From 280 assessable prescriptions, 141 (50.4%) were compliant with guidelines. Treating specialties, administration route, class of antimicrobial, and the number of prescriptions per patient were contributing factors associated with compliance. On multivariate analysis, administering non-oral routes of antimicrobial administration, and single antimicrobial prescription prescribed per patient was independently associated with non-compliance. NAPS can produce robust baseline information and identifying targets for improvement in antimicrobial prescribing in reference to current AMS initiatives within the tertiary care teaching hospital. The findings underscore the necessity to expand the AMS efforts towards reinforcing compliance, documentation, improving surgical prophylaxis prescribing practices, and updating local antibiotic guidelines.
Identifiants
pubmed: 34064457
pii: antibiotics10050531
doi: 10.3390/antibiotics10050531
pmc: PMC8148015
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Pfizer
ID : 40867041
Références
Drugs. 2011 Apr 16;71(6):745-55
pubmed: 21504250
Clin Infect Dis. 2017 May 15;64(suppl_2):S61-S67
pubmed: 28475790
Intern Med J. 2012 Jun;42(6):719-21
pubmed: 22697156
Clin Infect Dis. 2009 Nov 15;49(10):1496-504
pubmed: 19842976
Antimicrob Resist Infect Control. 2020 Jan 13;9(1):13
pubmed: 31956402
New Microbes New Infect. 2015 Apr 16;6:22-9
pubmed: 26029375
J Infect Public Health. 2019 Jan - Feb;12(1):77-82
pubmed: 30270148
J Glob Antimicrob Resist. 2019 Jun;17:291-295
pubmed: 30668994
ANZ J Surg. 2002 Apr;72(4):275-8
pubmed: 11982514
J Antimicrob Chemother. 2015;70(6):1912-8
pubmed: 25724986
Clin Microbiol Infect. 2014 Oct;20(10):963-72
pubmed: 25039787
Springerplus. 2014 Dec 09;3:717
pubmed: 25674457
J Hosp Infect. 2019 Nov;103(3):280-283
pubmed: 31170422
Int J Infect Dis. 2016 Aug;49:87-93
pubmed: 27235085
PLoS Med. 2015 May 19;12(5):e1001825
pubmed: 25992781
Euro Surveill. 2018 Nov;23(46):
pubmed: 30458917
Open Forum Infect Dis. 2018 May 24;5(6):ofy110
pubmed: 29977965
J Antimicrob Chemother. 2011 Feb;66(2):443-9
pubmed: 21084362
Swiss Med Wkly. 2019 Oct 27;149:w20135
pubmed: 31656037
Lancet Infect Dis. 2016 Dec;16(12):e276-e287
pubmed: 27816413
Swiss Med Wkly. 2018 Apr 26;148:w14617
pubmed: 29698542
Neth J Med. 2015 May;73(4):161-8
pubmed: 25968287
J Infect Public Health. 2015 Jan-Feb;8(1):55-61
pubmed: 25129448
J Antimicrob Chemother. 2016 Aug;71(8):2295-9
pubmed: 27121400
Lancet Glob Health. 2018 Jun;6(6):e619-e629
pubmed: 29681513
Lancet Infect Dis. 2010 Mar;10(3):167-75
pubmed: 20185095
MMWR Morb Mortal Wkly Rep. 1999 Jul 30;48(29):621-9
pubmed: 10458535
Antimicrob Resist Infect Control. 2015 Jun 04;4:24
pubmed: 26075065
Infect Control Hosp Epidemiol. 2016 Oct;37(10):1201-11
pubmed: 27418168
Expert Rev Anti Infect Ther. 2019 Apr;17(4):285-293
pubmed: 30755077
Int J Environ Res Public Health. 2018 Dec 23;16(1):
pubmed: 30583571
J Hosp Infect. 2020 Feb;104(2):165-171
pubmed: 31678430